Mitochondrial dysfunction drives age-related degeneration of the thoracic aorta.

Dhanekula AS, Harrison BR, Pharaoh G, Mattson-Hughes A, Tarantini S, Stuppard R, DeRoo SC, Burke CR, Hwang B, Pal JD, Mulligan MS, Marcinek DJ

GeroScience13 Nov 2025Cited by 4 (Europe PMC)

PMID41233677PMCIDPMC13575079DOI10.1007/s11357-025-01937-7PepBankPUB-41233677

Source link PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In aged mice, elamipretide restored complex II-linked respiration to values seen in young mice.
In plain wordsIn old mice, elamipretide brought aortic mitochondrial respiration back to the level seen in young mice.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseComplex II-linked respiration in aorta
Study
mousen: not reported in source
young and aged C57Bl/6 J mice
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated · 8 weeksAs given in this study (mouse).
Source sentences
Summary
ELAM restored complex II-linked respiration in aged mice to values seen in young mice
1 context sentence(design, population, supporting numbers)
Summary · context
Both male and female young (5-6 month) and aged (24-25 month) C57Bl/6 J mice received mitochondrial-targeted peptide elamipretide (ELAM; SS-31) for 8 weeks.
Report a problemFND-4123367701
02AnimalAnimal study (in vivo)Efficacy outcome
In aged mice, elamipretide improved relative phosphorylative flux in the aorta.
In plain wordsIn old mice, elamipretide improved how well aortic mitochondria make energy.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseRelative phosphorylative flux
Study
mousen: not reported in source
young and aged C57Bl/6 J mice
Outcome group
Mitochondrial function · Cardiovascular
Studied dose
Dose not stated · 8 weeksAs given in this study (mouse).
Source sentences
Summary
ELAM restored complex II-linked respiration in aged mice to values seen in young mice, while also improving relative phosphorylative flux.
1 context sentence(design, population, supporting numbers)
Summary · context
Both male and female young (5-6 month) and aged (24-25 month) C57Bl/6 J mice received mitochondrial-targeted peptide elamipretide (ELAM; SS-31) for 8 weeks.
Report a problemFND-4123367702
03AnimalAnimal study (in vivo)Efficacy outcome
In aged mice, elamipretide reduced inflammatory MMP9 expression in the aorta.
In plain wordsIn old mice, elamipretide lowered an inflammatory protein, MMP9, in the aorta.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseMMP9 expression
Study
mousen: not reported in source
young and aged C57Bl/6 J mice
Outcome group
Inflammation markers · Cardiovascular
Studied dose
Dose not stated · 8 weeksAs given in this study (mouse).
Source sentences
Summary
ELAM treatment also reduced inflammatory MMP9 expression and elastin breaks in aged mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Both male and female young (5-6 month) and aged (24-25 month) C57Bl/6 J mice received mitochondrial-targeted peptide elamipretide (ELAM; SS-31) for 8 weeks.
Report a problemFND-4123367703
04AnimalAnimal study (in vivo)Efficacy outcome
In aged mice, elamipretide reduced elastin breaks in the aorta.
In plain wordsIn old mice, elamipretide reduced breaks in the elastic fibres of the aorta.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseElastin breaks
Study
mousen: not reported in source
young and aged C57Bl/6 J mice
Outcome group
Aging markers · Cardiovascular
Studied dose
Dose not stated · 8 weeksAs given in this study (mouse).
Source sentences
Summary
ELAM treatment also reduced inflammatory MMP9 expression and elastin breaks in aged mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Both male and female young (5-6 month) and aged (24-25 month) C57Bl/6 J mice received mitochondrial-targeted peptide elamipretide (ELAM; SS-31) for 8 weeks.
Report a problemFND-4123367704
05AnimalAnimal study (in vivo)Mechanism
In mice, elamipretide affected the aortic transcriptome in an age-dependent manner, reducing expression of senescent and associated pro-inflammatory genes.
In plain wordsIn mice, elamipretide lowered the activity of aging-related and inflammatory genes in the aorta.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseSenescent and pro-inflammatory gene expression
Study
mousen: not reported in source
young and aged C57Bl/6 J mice
Outcome group
Aging markers · Cardiovascular
Studied dose
Dose not stated · 8 weeksAs given in this study (mouse).
Source sentences
Summary
Bulk RNAseq analysis revealed that ELAM treatment significantly affected the aortic transcriptome in an age-dependent manner, reducing the expression of senescent and associated pro-inflammatory genes.
1 context sentence(design, population, supporting numbers)
Summary · context
Both male and female young (5-6 month) and aged (24-25 month) C57Bl/6 J mice received mitochondrial-targeted peptide elamipretide (ELAM; SS-31) for 8 weeks.
Report a problemFND-4123367705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.